S&P 500
7,515.00
+0.21%
Dow Jones
52,458.40
+0.24%
Nasdaq 100
29,958.20
-1.09%
Russell 2000
3,029.54
+0.19%
FTSE 100
10,498.70
-0.34%
Nikkei 225
69,807.30
-1.69%
Stock Market Live July 1, 2026: S&P 500 (SPY) Lower as Investors Wait on the Fed and Fresh Economic Data
Ashland

Ashland (ASH) Q4 2025 Earnings

Reported Nov 4, 2025 at 5:07 PM ET · SEC Source

Q4 25 EPS

$1.08

MISS 14.62%

Est. $1.26

Q4 25 Revenue

$478.0M

MISS 0.76%

Est. $481.7M

vs S&P Since Q4 25

+30.7%

BEATING MARKET

ASH +41.0% vs S&P +10.3%

Full Year 2025 Results

FY 25 EPS

$3.38

MISS 4.89%

Est. $3.55

FY 25 Revenue

$1.82B

MISS 0.13%

Est. $1.83B

Market Reaction

Did ASH Beat Earnings? Q4 2025 Results

Ashland delivered a disappointing close to fiscal 2025, with fourth-quarter results missing on both the top and bottom lines as persistent market headwinds and deliberate portfolio reshaping weighed on performance. Adjusted diluted EPS came in at $1.… Read more Ashland delivered a disappointing close to fiscal 2025, with fourth-quarter results missing on both the top and bottom lines as persistent market headwinds and deliberate portfolio reshaping weighed on performance. Adjusted diluted EPS came in at $1.08, falling short of the $1.30 consensus estimate by 16.92%, while revenue of $478.00 million declined 8.4% year-over-year and landed just below the $479.36 million expectation. The primary culprit was Ashland's own Portfolio Optimization program, which stripped roughly $38.00 million from sales through divestitures of the Nutraceuticals and Avoca businesses and product line rationalizations; excluding those actions, organic sales fell only one percent. Adjusted EBITDA of $119.00 million represented a 25% margin, though Life Sciences and Personal Care offered brighter spots, with the former exceeding 30% Adjusted EBITDA margin for the first time. Looking ahead, Ashland guided fiscal 2026 sales of $1.83 billion to $1.91 billion and Adjusted EBITDA of $400.00 million to $430.00 million, targeting double-digit-plus adjusted EPS growth as restructuring savings and innovation initiatives begin to take hold.

Key Takeaways

  • • Portfolio Optimization initiatives reduced sales by approximately $38 million but improved margin profile
  • • Restructuring savings of approximately $30 million realized in fiscal 2025
  • • Improved product mix and lower SARD expenses drove Adjusted EBITDA growth ex-Portfolio Optimization
  • • Share repurchase activity reduced diluted shares from 49 million to 46 million year-over-year
  • • Personal Care delivered 5% organic sales growth with double-digit growth in globalize business lines
  • • Life Sciences pharma demand resilient with low-single-digit sales growth year-over-year
  • • Foreign currency movements contributed favorable $8 million to sales
24/7 Wall St

ASH YoY Financials

Q4 2025 vs Q4 2024, source: SEC Filings

24/7 Wall St

ASH Revenue by Segment

With YoY comparisons, source: SEC Filings

Q2 25 Q1 26

“Ashland's fourth-quarter performance reflects our disciplined approach and ability to deliver results in line with expectations, even as market conditions remained challenging. We maintained strong margins and delivered revenue and EBITDA consistent with prior guidance. Our continued focus on execution helped offset pockets of competitive pressure and muted demand.”

— Guillermo Novo, Q4 2025 Earnings Press Release

Back to ASH Stock Page